Ventyx emerges with $114M to bring asset-centric immunology plays under one umbrella

Ventyx is the second start-up in the past month to bundle asset-centric companies under one umbrella with an eye towards advancing each program faster than the originator companies could have had they remained independent. The company, which launched Tuesday with a $114 million round led by venBio, plans to develop three small molecules in parallel across a range of immunology indications. 

Centessa Pharmaceuticals Inc. launched last month with a similar model, bundling 10 Medicxi portfolio companies under a single parent...